Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2019-02-14 |
Passage Bio (USA - PA) |
$115.5 million |
series A financing round |
OrbiMed Advisors (USA - NY) Frazier Healthcare Partners (USA - WA) Versant Ventures (USA - CA) New Leaf Venture Partners (USA - NY - CA) Vivo Capital (USA - CA) Lilly Asia Ventures (China) |
Rare diseases - Genetic diseases - CNS diseases |
Series A financing round |
2019-01-25 |
Nordic Nanovector (Norway) |
NOK 222 million ($ 26 million) |
private placement |
|
Cancer - Oncology |
Private placement |
2019-01-25 |
Corbus Pharmaceuticals (USA - MA) |
|
private placement |
|
Inflammatory diseases |
Private placement |
2019-01-24 |
Wave Life Sciences (USA - MA) |
$150 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2019-01-24 |
Wave Life Sciences (USA - MA) |
$150 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2019-01-23 |
Orion (Finland) |
€ 100 million |
loan |
European Investment Bank (EIB) |
Cancer - Oncology - Neurological diseases - Respiratory diseases |
Loan |
2019-01-23 |
PTC Therapeutics (USA - NJ) |
|
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2019-01-23 |
Selecta Biosciences (USA - MA) |
$30 million |
private placement |
|
|
Private placement |
2019-01-22 |
Alvotech (Iceland) |
$300 million |
private placement |
|
Autoimmune diseases - Inflammatory diseases - Cancer - Oncology |
Private placement |
2019-01-04 |
Aimmune Therapeutics (USA - CA) |
$ 170 million |
loan |
KKR (USA - NY) |
Allergic diseases |
Loan |
2019-01-03 |
Cabaletta Bio (USA - PA) |
$50 million |
series B financing round |
Adage Capital (USA - MA) 5AM Ventures (USA - MA) Deerfield Management Company (USA - NY) Boxer Capital of Tavistock Group (Bahamas) Redmile Group (USA - CA) Cormorant Capital (USA - IL) |
Autoimmune diseases |
Series B financing round |
2018-12-21 |
Nabriva Therapeutics (Ireland) |
$75 million |
loan |
Hercules Capital (USA - CA) |
Infectious diseases |
Loan |
2018-12-20 |
Geneuro (Switzerland) |
€7.5 million |
credit line |
GNEH (France) |
Neurodegenerative diseases |
Loan |
2018-12-14 |
Axovant Sciences (Bermuda - USA - NY) |
$ 30 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2018-11-26 |
Adrenomed (Germany) |
€ 24 million |
series D financing round |
HBM Healthcare Investments (Switzerland) Wellington Partners (Germany - UK) |
Inflammatory diseases |
Series D financing round |
2018-11-02 |
Omeicos Therapeutics (Germany) |
€ 17 million |
series C financing round |
Forbion Capital Partners (The Netherlands) Vesalius Biocapital (Luxembourg) SICAR (Luxembourg) VC Fonds Technologie Berlin (Germany) Hightech Gruenderfonds II GmbH & Co. KG (HTGF) (Germany) KfW Group (Germany) The Falck Revocable Trust, members of the management |
Cardiovascular diseases - Ophtalmological diseases |
Series C financing round |
2018-10-30 |
Orchard Therapeutics (UK) |
|
IPO |
|
Rare diseases - Genetic diseases |
IPO |
2018-10-30 |
Newron Pharmaceuticals (Italy) |
€ 40 million |
loan |
European Investment Bank (EIB) |
CNS diseases - Neurological diseases |
Loan |
2018-10-25 |
89Bio (USA - CA) |
$60 million |
series A financing round |
OrbiMed (USA - NY) Longitude Capital (USA - CA) RA Capital Management (USA - MA) Pontifax (Israel) |
Hepatic diseases - Liver diseases |
Series A financing round |
2018-10-23 |
Cerevel Therapeutics (USA - MA) |
$350 million |
financing round |
Pfizer (USA - NY) Bain Capital (USA - MA) |
CNS diseases |
Financing round |